Evaluation of the hepatotoxic potential of citalopram in rats

Creative Commons License

ILGIN S., Dagasan F., BURUKOĞLU DÖNMEZ D., BAYSAL M., ATLI EKLİOĞLU Ö.

ISTANBUL JOURNAL OF PHARMACY, vol.50, no.3, pp.188-194, 2020 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 50 Issue: 3
  • Publication Date: 2020
  • Doi Number: 10.26650/istanbuljpharm.2019.0081
  • Journal Name: ISTANBUL JOURNAL OF PHARMACY
  • Journal Indexes: Emerging Sources Citation Index (ESCI)
  • Page Numbers: pp.188-194
  • Keywords: Citalopram, hepatotoxicity, hepatic biomarker, liver histology, oxidative status, INDUCED LIVER-INJURY, SEROTONIN REUPTAKE INHIBITORS, DRUG, ANTIDEPRESSANTS, ESCITALOPRAM, METABOLITES, MECHANISMS, DIAGNOSIS, PLACEBO
  • Anadolu University Affiliated: Yes

Abstract

Background and Aims: Citalopram is a selective serotonin reuptake inhibitor with a high potency which is occasionally prescribed and used to treat major depression associated with mood disorders as a first-line drug. According to the results of previous studies, evidence of hepatotoxicity related to citalopram treatment were limited and conflicting. Therefore, we aimed to evaluate the hepatotoxicity potential of sub-chronic citalopram administration.